Related Experiment Videos
Hypothesis: breast cancer regression under oestrogen therapy
British Medical Journal
|August 25, 1973
Summary
High-dose estrogen therapy for advanced breast cancer may not work as expected. Treatment effectiveness hinges on the balance of estrogen and prolactin levels at the tumor site, not just hormone binding or prolactin inhibition.
Area of Science:
- Endocrinology
- Oncology
- Pharmacology
Background:
- Established mechanisms for estrogen therapy in breast cancer include direct tumor cell effects and prolactin inhibition.
- Recent findings challenge these traditional explanations for treatment efficacy.
Purpose of the Study:
- To investigate anomalies observed in advanced breast cancer patients treated with high-dose estrogen therapy.
- To propose an alternative hypothesis for estrogen's therapeutic effects based on hormone concentrations.
Main Methods:
- Review of clinical responses in 407 advanced breast cancer patients treated with estrogen therapy.
- Analysis of patient age, tumor response, dosage, site sensitivity, and effects of estrogen withdrawal.
Main Results:
- Observed anomalies include age-dependent tumor responses, dose-dependent effects, differential sensitivity across tumor sites, and regression upon estrogen withdrawal.
- Tumor stimulation during estrogen therapy suggests inadequate local estrogen concentration.
Conclusions:
- The efficacy of high-dose estrogen therapy in breast cancer may critically depend on the absolute and relative concentrations of prolactin and estrogen at the tumor.
- Tumoral factors, such as receptor levels for estradiol and prolactin, may influence site-specific sensitivity and treatment outcomes.